# Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

> **NCT00105235** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 27 (actual)

## Conditions studied

- Liver Disease
- Liver Transplantation

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Cyclosporine
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Tacrolimus
- **PROCEDURE:** Liver transplant
- **PROCEDURE:** Immunosuppression withdrawal

## Key facts

- **NCT ID:** NCT00105235
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-03
- **Final completion:** 2011-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105235, "Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00105235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*